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A B S T R A C T 
Introduction: The management of human epidermal 
growth factor receptor 2 (HER2)–positive breast 
cancer has changed dramatically with the introduction 
and widespread use of HER2-targeted therapies. There 
is, however, relatively limited real-world information 
about the effectiveness and safety of trastuzumab 
emtansine (T-DM1) in Hong Kong Chinese patients. 
We assessed the efficacy and toxicity profiles among 
local patients with HER2-positive advanced breast 
cancer who had received T-DM1 therapy in the 
second-line setting and beyond.
Methods: This retrospective study involved five 
local centres that provide service for over 80% of 
the breast cancer population in Hong Kong. The 
study period was from December 2013 to December 
2015. Patients were included if they had recurrent 
or metastatic histologically confirmed HER2+ breast 
cancer who had progressed after at least one line of 
anti-HER2 therapy including trastuzumab. Patients 
were excluded if they received T-DM1 as first-
line treatment for recurrent or metastatic HER2+ 
breast cancer. Patient charts including biochemical 
and haematological profiles were reviewed for 
background information, T-DM1 response, and 
toxicity data. Adverse events were documented 
during chemotherapy and 28 days after the last dose 
of medication.
Results: Among 37 patients being included in this 
study, 28 (75.7%) had two or more lines of anti-HER2 
agents and 26 (70.3%) had received two or more lines 
of palliative chemotherapy. Response assessment 
revealed that three (8.1%) patients had a complete 
response, eight (21.6%) a partial response, 11 (29.7%) 
a stable disease, and 12 (32.4%) a progressive disease; 
three patients could not be assessed. The median 
duration of response was 17.3 (95% confidence 
interval, 8.4-24.8) months. The clinical benefit rate 
(complete response + partial response + stable 
disease, ≥12 weeks) was 37.8% (95% confidence 
interval, 22.2%-53.5%). The median progression-
free survival was 6.0 (95% confidence interval, 3.3-
9.8) months and the median overall survival had 
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New knowledge added by this study
• This study confirms that the efficacy and toxicity profiles of trastuzumab emtansine (T-DM1) among Chinese 
patients are similar to the published data that have been based mainly on western populations.
Implications for clinical practice or policy
• T-DM1 is effective in HER2-positive advanced breast cancer in the second-line setting and beyond. It has 
tolerable toxicity. Further research is warranted to enable identification of the appropriate patient population to 
enhance cost-effectiveness.
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not been reached by the data cut-off date. Grade 3 
or 4 toxicities included thrombocytopaenia (13.5%), 
raised alanine transaminase (8.1%), anaemia (5.4%), 
and hypokalaemia (2.7%). No patient died as a result 
of toxicities.
Conclusions: In patients with HER2-positive 
advanced breast cancer who have been heavily 
pretreated with anti-HER2 agents and cytotoxic 
chemotherapy, T-DM1 is well tolerated and provided 
a meaningful progression-free survival of 6 months 
and an overall survival that has not been reached. 
Further studies to identify appropriate patient 
subgroups are warranted.
This article was 
published on 12 Jan 
2018 at www.hkmj.org.
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Breast cancer is the most common female cancer 
in Hong Kong. The human epidermal growth 
factor receptor HER2/neu gene is amplified and 
overexpressed in 15% to 25% of breast cancers.1 The 
management of human epidermal growth factor 
receptor 2 (HER2)–positive (HER2+) breast cancer 
has changed dramatically with the introduction 
and widespread use of HER2-targeted therapies. 
The landmark study reported by Slamon et al2 
over a decade ago established the combination of 
trastuzumab with chemotherapy as the standard 
of care for patients with HER2+ metastatic breast 
cancer. The later CLEOPATRA trial showed that the 
combination of pertuzumab with trastuzumab and 
chemotherapy (specifically, docetaxel) could further 
improve survival when compared with the standard 
arm of trastuzumab plus chemotherapy in the first-
line setting.3 
 Trastuzumab emtansine (T-DM1) is an 
antibody-drug conjugate that incorporates the HER2-
targeted antitumour properties of trastuzumab with 
the cytotoxic activity of the microtubule inhibitor 
DM1 (which is a derivative of maytansine). The 
high potency of the cytotoxic DM1 moiety has been 
suggested as a key factor in the enhanced activity 
of this compound.4,5 In the second-line setting, 
the pivotal EMILIA study compared T-DM1 with 
lapatinib plus capecitabine among patients with 
HER2+ breast cancer who had previously been 
treated with trastuzumab and a taxane; T-DM1 
showed remarkable activity with an acceptable 
toxicity profile.6 There is, however, relatively limited 
real-world information about the effectiveness and 
safety of T-DM1 in Hong Kong Chinese patients.
 In this multicentre retrospective study, we 
assessed the efficacy and toxicity profiles among 
local patients with HER2+ advanced breast cancer 
who had received T-DM1 therapy in the second-line 
setting and beyond.
Methods
This was a retrospective study that involved five 
local centres that care for over 80% of the local 
breast cancer population, and included the Pamela 
Youde Nethersole Eastern Hospital, Prince of 
Wales Hospital, Queen Mary Hospital, Queen 
Elizabeth Hospital, and Tuen Mun Hospital between 
December 2013 and December 2015, the period 
when the relevant treatment was first started. The 
institutional ethics committee of each participating 
centre approved the study. 
 Inclusion criteria included patients who had 
recurrent or metastatic histologically confirmed 
HER2+ breast cancer who either had progressed 
during trastuzumab with chemotherapy in the first-
line treatment setting, or had developed progressive 
disease after at least one line of anti-HER2 agent 
including trastuzumab. Patients who had received 
endocrine therapy for recurrent or metastatic 
disease were included. Exclusion criteria included 
patients who received T-DM1 as first-line treatment 
for recurrent or metastatic HER2+ breast cancer. 
 Patient charts were reviewed for background 
information, T-DM1 response, and toxicity data 
by medical staff who were not blinded to the 
study objectives. Biochemical and haematological 
profiles were extracted from patient charts. 
Tumour response assessments were recorded 
according to the Response Evaluation Criteria in 
Solid Tumors Committee.7 Adverse events were 
graded according to the National Cancer Institute’s 
Common Terminology Criteria for Adverse Events 
(version 3.0). Adverse events were also documented 
during chemotherapy and 28 days after the last dose 
of study medication. 
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Statistical analysis
Outcomes in terms of tumour response, progression-
free survival (PFS), and overall survival (OS) were 
determined. The PFS was assessed from day 1 of 
treatment cycle 1 to the date when objective disease 
progression was observed, and OS was calculated 
from day 1 of treatment cycle 1 to the date of death. 
Death was regarded as a progression event in those 
subjects who died before disease progression. 
Subjects without documented objective progression 
at the time of the final analysis were censored at the 
date of their last tumour assessment; data cut-off was 
on 31 August 2016. Survival curves were constructed 
using the Kaplan-Meier method.  
Results
Patient characteristics
Patient characteristics are shown in Table 1. Of 
a total of 37 patients, 33 (89.2%) had an Eastern 
Cooperative Oncology Group performance status of 
0 or 1. 
 Of the 37 patients, tumour biology studies at 
initial disease presentation showed that 15 (40.5%) 
TABLE 1.  Patient characteristics and prior treatments (n=37) TABLE 1.  (cont'd)
Characteristic Median (range) 
or No. (%) of 
patients/sites/
cycles
Age (years) 52 (29-70)




Time since last anti-HER2 therapy 32 (14-274)















Neo/Adjuvant trastuzumab 13 (35.1)
Neo/Adjuvant chemotherapy
Anthracycline-containing only 6 (16.2)
Taxane-containing only 7 (18.9)
Anthracycline- and taxane-containing 8 (21.6)
Neo/Adjuvant endocrine therapy
Tamoxifen 7 (18.9)
Aromatase inhibitors 1 (2.7)
Adjuvant radiation therapy 19 (51.4)
Prior treatment for recurrent/metastatic 
disease








Abbreviations: ECOG PS = Eastern Cooperative Oncology 
Group performance status; HER2 = human epidermal growth 
factor receptor 2
* As first-line anti-HER2 treatment, 6 patients received 
trastuzumab, 3 patients received trastuzumab and 
pertuzumab 
† Others included fluorouracil, cyclophosphamide, carboplatin, 
pemetrexed, etoposide, and nab-paclitaxel
Characteristic Median (range) 
or No. (%) of 
patients/sites/
cycles
Prior treatment for recurrent/metastatic 
disease (cont’d)

















Prior endocrine therapy 
Tamoxifen 8 (21.6)
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patients were oestrogen receptor (ER)–positive, 10 
(27.0%) were progesterone receptor (PR)–positive, 
and 31 (83.8%) had HER2+ breast cancer. Overall, 
21 patients had tumour re-biopsy at the time of 
developing metastatic disease, 10 (47.6%) patients 
were ER-positive, nine (42.9%) PR-positive, and 21 
(100%) had HER2+ (which included six patients 
who were found to have HER2+ tumours only when 
anti-HER2 therapy was considered for metastatic 
disease).
 At the time of initiating T-DM1 therapy, 21 
patients had three or more disease sites involved; the 
most common sites included lymph nodes (n=27, 
73.0%), lungs (n=20, 54.1%), and bones (n=19, 
51.4%).
Prior treatments
Prior treatments that patients received are listed 
in Table 1. With regard to adjuvant treatments, 13 
(35.1%) patients had prior adjuvant trastuzumab, 21 
(56.8%) had adjuvant chemotherapy, eight (21.6%) 
had adjuvant endocrine therapy, and 19 (51.4%) had 
adjuvant radiotherapy.
 With regard to treatment for recurrent/
metastatic disease, nine (24.3%) patients had one line 
of prior trastuzumab with chemotherapy including 
three who had trastuzumab in combination with 
pertuzumab and chemotherapy; 11 (29.7%) had 
two lines while 17 (45.9%) had three or more lines 
of anti-HER2 therapy. Overall, 22 (59.5%) patients 
had received prior lapatinib, and five (13.5%) had 
received pertuzumab beyond the first-line setting.
 A total of 26 (70.3%) patients had received 
two or more lines of palliative chemotherapy, 
with the majority having received taxanes (n=33, 
89.2%), capecitabine (n=23, 62.2%) and vinorelbine 
(n=17, 45.9%). Nineteen patients had received one 
or more lines of palliative endocrine therapy, these 
included eight (21.6%) with tamoxifen, 15 (40.5%) 
with aromatase inhibitors, and seven (18.9%) with 
ovarian ablation. 
Trastuzumab emtansine dose and dose 
interruptions
The median number of days from last anti-HER2 
therapy to the first dose of T-DM1 was 32 days 
(range, 14-274 days). 
 The median number of cycles was six 
(range, 1-43). The follow-up data were frozen on 
31 August 2016. The median follow-up period 
was 15.6 months (95% confidence interval [CI], 
8.1-20.4 months). Overall, 33 patients were 
started on the standard dose of 3.6 mg/kg, 
given once every 3 weeks; 13 patients had dose 
delay, 10 patients had dose reduction for subsequent 
cycles, and six patients had both dose delay and dose 
reductions for subsequent cycles. A total of 326 
cycles were administered; 44 (13.5%) cycles were 
delayed, 11 (3.4%) cycles had further dose reductions 
in the subsequent cycles, and 51 (15.6%) cycles had 
both dose delay and dose reductions.
 At the time of data cut-off, 28 had discontinued 
T-DM1 treatment: 20 (71.4%) due to progressive 
disease, four (14.3%) were lost to follow-up, one 
(3.6%) due to patient withdrawal, and three (10.7%) 
due to unspecified causes. No patient discontinued 
treatment due to intolerable toxicities.
Response and survival
Among the 37 patients, there were three (8.1%) 
complete response (CR), eight (21.6%) partial 
response (PR), 11 (29.7%) stable disease (SD), and 12 
(32.4%) progressive disease; three patients could not 
be assessed (ie they did not have response assessment 
documented during their treatment). The median 
duration of response was 17.3 months (interquartile 
range, 9.4-24.5; 95% confidence interval, 8.4-24.8 
months). The clinical benefit rate, defined as CR, 
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PR, or SD of 12 weeks or longer, was 37.8% (95% CI, 
22.2%-53.5%). 
 Overall, based on the Kaplan-Meier method, 
the median PFS was 6.0 (95% CI, 3.3-9.8) months; 
the 6-month and 12-month PFSs were 51.6% and 
23.1%, respectively (Fig a). The median duration of 
follow-up for PFS was 5.0 (interquartile range, 2.2-
10.3) months. The median OS was not reached; the 
6-month and 12-month OSs were 82.1% and 74.4%; 
respectively (Fig b).
Toxicity
Haematological and non-haematological toxicities 
are listed in Table 2. Grade 3 or 4 toxicities 
that occurred in one or more patients included 
thrombocytopenia (n=5, 13.5%), raised alanine 
transaminase (n=3, 8.1%), anaemia (n=2, 5.4%), 
and hypokalaemia (n=1, 2.7%). Apart from these, 
other toxicities that occurred in more than 10% 
of patients included raised alkaline phosphatase, 
hyponatraemia, neutropenia, leukopenia, fatigue, 
raised serum creatinine, and diarrhoea. There was 
no cardiac toxicity and no patients died as a result 
of toxicities.
Discussion 
During the past decade, the treatment of HER2+ 
breast cancer has rapidly evolved, and patients with 
HER2+ metastatic breast cancer have experienced 
a remarkable improvement in clinical outcomes in 
terms of OS.8
 The efficacy of T-DM1 was well demonstrated 
in the pivotal EMILIA study that compared T-DM1 
with lapatinib plus capecitabine among HER2+ 
breast cancer patients in the second-line setting. The 
studied patients had previously been treated with 
trastuzumab and a taxane. For the T-DM1–treated 
patients, the objective response rate was 44%, the 
median PFS was 9.6 months, and the median OS was 
30.9 months.6 
 In the current multicentre retrospective study 
among the Chinese patients with breast cancer, over 
70% were heavily pretreated with anti-HER2 agents 
as well as cytotoxic chemotherapy. The efficacy 
results are consistent with previous findings from 
the TH3RESA study.9 The latter involved over 600 
HER2+ patients with advanced breast cancer who 
had received two or more anti-HER2–containing 
regimens, including trastuzumab and lapatinib, and 
previous taxane therapy. At a median follow-up of 6.5 
months, the TH3RESA study reported that among 
the T-DM1–treated patients, the objective response 
rate was 31%, the median duration of response was 
9.7 months, the median PFS was 6.2 months, and 
the median OS was not reached.9 Similarly, the 
safety profile in the current study was consistent 
with the reported clinical trials, where grade 3 or 
worse thrombocytopenia was the most commonly 
reported adverse event (13.5%), followed by raised 
alanine transaminase (8.1%), anaemia (5.4%), and 
hypokalaemia (2.7%). Notably there was no grade 3 
or worse neutropenia, no febrile neutropenia, and 
no cardiac toxicity noted in the current study. 
 In heavily pretreated patient populations, 
two studies, namely the TH3RESA study9 and the 
EGF104900 study10 (which assessed combination 
of trastuzumab and lapatinib in the absence of 
chemotherapy), have shown that even after a median 
of four prior regimens, the use of anti-HER2 therapy 
can lead to meaningful clinical benefits. In the 
TH3RESA study, the PFS benefit with T-DM1 was 
observed in subgroups including hormone receptor–
positive tumours and non-visceral disease, as well 
as asymptomatic or treated brain metastases. An 
exploratory analysis conducted in the present study 
TABLE 2.  Haematological and non-haematological toxicities according to the 
National Cancer Institute Common Toxicity Criteria version 3.0 (n=37)
Grade
0 1 2 3 4 5
Thrombocytopenia 20 8 4 3 2 0
Raised alanine transaminase 19 14 1 3 0 0
Anaemia 28 6 1 2 0 0
Hypokalaemia 29 7 0 1 0 0
Hypoalbuminaemia (n=33) 30 0 3 0 0 0
Raised alkaline phosphatase 28 7 2 0 0 0
Hyponatraemia 33 2 2 0 0 0
Neutropenia 32 4 1 0 0 0
Hyperbilirubinaemia 34 2 1 0 0 0
Left ventricular ejection fraction 35 1 1 0 0 0
Leukopenia 32 5 0 0 0 0
Fatigue 32 5 0 0 0 0
Creatinine 33 4 0 0 0 0
Diarrhoea 33 4 0 0 0 0
Stomatitis 35 2 0 0 0 0
Nausea 35 2 0 0 0 0
Anorexia 36 1 0 0 0 0
High plasma urea (n=33) 32 1 0 0 0 0
Rash 36 1 0 0 0 0
Septic episode 36 1 0 0 0 0
Raised aspartate transaminase 36 1 0 0 0 0
Heartburn 36 1 0 0 0 0
Malaise 36 1 0 0 0 0
Sensory neuropathy 36 1 0 0 0 0
Myalgia 36 1 0 0 0 0
Peripheral numbness 36 1 0 0 0 0
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revealed that the median PFSs for patients with 
hormone receptor–positive disease and hormone 
receptor–negative disease were 7.5 and 6.0 months, 
respectively. Owing to small patient numbers, the 
finding was not significant (P=0.78) but nonetheless 
lends support to the published data.
 Among the 37 patients in the current study, 
five had prior pertuzumab therapy in addition to 
trastuzumab (including one who also had lapatinib). 
One of these patients achieved PR and had a total 
of eight cycles of T-DM1 treatment. The efficacy 
of T-DM1 among patients previously treated with 
trastuzumab and pertuzumab has recently been 
reported in a retrospective study.11 Although the 
response rate was relatively low at 18%, 30% of the 
patients had received prolonged T-DM1 therapy, 
defined as treatment duration of 6 months or longer. 
 It has to be noted that despite the efficacy 
shown in the second-line and beyond setting among 
HER2+ patients with advanced breast cancer, the 
MARIANNE study, which tested three different 
anti-HER2 regimens in the first-line setting, did not 
show T-DM1 to be superior to standard treatment.12 
In that study, previously untreated patients with 
HER2+ metastatic breast cancer were randomised 
to one of the three arms: control (trastuzumab plus 
taxane), T-DM1 alone, or T-DM1 plus pertuzumab. 
Although the results revealed that grade 3 or higher 
adverse events were lower in the T-DM1 arm, efficacy 
data on PFS were similar in all three arms, at 13.7 
months, 14.1 months, and 15.2 months, respectively. 
In another exploratory analysis in the present study, 
the PFS of those patients who had undergone only 
one line of prior anti-HER2 therapy was compared 
with those who had two or more lines of anti-HER2 
therapy revealed corresponding figures of 8.2 and 5.1 
months, respectively (P=0.34).
 In addition, cost-effective analysis has been 
conducted in a number of countries with regard 
to the use of T-DM1. For patients with HER2+ 
metastatic breast cancer, the Canadian analysis 
demonstrated that utilising T-DM1 could lead to 
substantial savings for the public health care system 
when the costs of treatment-related adverse events 
incurred by other anti-cancer agents were taken into 
account.13 Nonetheless, analyses based in the United 
Kingdom and the United States have not supported 
such findings.14-16 
 The identification of an appropriate patient 
population for the utilisation of T-DM1 may enable 
better resource allocation. Yet to date, no biomarkers 
have been identified that can predict better outcome 
among patients with HER2+ advanced breast cancer 
treated with T-DM1. Based on the biomarker 
analyses from EMILIA and TH3RESA studies, 
T-DM1 was similarly effective in the presence of 
PI3K wild-type or mutated tumours, and the benefit 
with T-DM1 was seen irrespective of HER2 mRNA, 
HER3 mRNA, or PTEN protein level.17,18
 The current study is limited by its retrospective 
design, possible information bias during data 
retrieval/extraction/coding, as well as the small 
number of patients (especially for subgroup 
analysis) and inadequate follow-up period for 
OS. Although the results could not be compared 
directly with reported prospective trials, patients 
were representative, and treatment and outcomes 
reflect routine clinical practice. The T-DM1 therapy 
provided a meaningful PFS with a favourable toxicity 
profile among heavily pretreated patients with 
HER2+ advanced breast cancer. Research is needed 
to identify biomarkers that will predict sensitivity 
and resistance to individual anti-HER2 agents, 
and thereby enable identification of those patients 
most likely to respond to T-DM1 and appropriate 
treatment to optimise patient benefit, reduce 
excessive toxicities, and minimise costs.
Conclusions
The T-DM1 therapy has a tolerable toxicity profile 
among local patients with recurrent or metastatic 
HER2+ breast cancer. For patients who responded to 
T-DM1 therapy, there was a durable response. In our 
study, T-DM1 is associated with a PFS of 6 months 
and an OS that has not been reached. Further 
biomarker study is needed to enable appropriate 
patient selection for this treatment.
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